The American laboratory Regeneron will pay at least 900 million dollars to the French pharmaceutical group Sanofi to obtain the exclusive license of Libtayo, a monoclonal antibody used in cancer treatments, Sanofi said in a press release Thursday.
To discover
Taxes 2022: all about your tax return
Read alsoCovid-19: WHO recommends Regeneron antibodies, but only in certain cases
Since 2015, the two laboratories have shared equally the operating profits generated by the sales of this drug worldwide.
With this new agreement, Sanofi will therefore transfer all of its rights to Libtayo to Regeneron for an initial payment of $900 million and royalties of 11% on worldwide sales, as well as additional payments depending on potential new approvals. of the drug.